The United Kingdom and the United States have established a landmark bilateral deal that will keep no tariffs on UK pharmaceutical shipments going into the American market.
Key Provisions of the Pact
As part of the deal, the UK has pledged to boost expenditure on pharmaceuticals through the National Health Service (NHS). This pledge ensures that duties on these crucial products will stay at nothing for a timeframe of 36 months.
This agreement comes after earlier statements to significantly raise import taxes on branded pharmaceutical products, with potential rates floated up to 100%.
"This deal with the United Kingdom strengthens the global environment for innovative medicines and brings long-overdue equity to American-British pharmaceutical trade," a statement declared.
Commercial Significance
Drugs represent one of the the United Kingdom's biggest exports to the America, which is clearly the biggest destination for major UK drugmakers.
Statistics reveal that in the year to the end of the third quarter, the UK sold medicines valued at over eleven billion pounds to the US. This figure made up nearly one-fifth of all goods exports in that timeframe.
"This guarantee secures employment, stimulates investment and sets the stage for the UK to become a international leader for medical research," the Business and Trade Secretary stated.
Key NHS Changes
The agreement includes several notable changes from the UK:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it deems new medicines to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a target to raise total public funding on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Rebate Cap: The amount drug companies must pay back to the NHS to prevent overspending will be limited at 15%. Last year, rebates exceeded twenty percent.
Broader Context
The pact comes amid a ongoing tension between the pharmaceutical industry and the British authorities over drug pricing and regulatory access.
The disagreement were heightened by claims that American consumers were charged significantly more for the same drugs than consumers in the Britain and the EU.
Recently, several significant drug company projects in the UK have been halted or abandoned, while major investments have been pledged toward projects in the United States.
The Science Minister stated that the NHS must spend more on medicines, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the last ten years.
